---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066242"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:33:22.818755+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Medical Group reiterates 2024 Adj. EBITDA guidance of $200M-$220M, portfolio optimization with $30M impact

## Summary
- Company exiting office-based practices and primary/urgent care by end of 2024.
- Annualized Adj. EBITDA impact of portfolio optimization ~$30M (based on 2023 results).
- Reiterates 2024 Adj. EBITDA guidance range of $200M to $220M, including in-year impact.
- Focus on operating efficiency and margin stabilization.

## SEC filing metadata
- accession: 0000950170-24-066242
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017024066242/0000950170-24-066242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017024066242/md-20240530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066242
- JSON: https://secwatch.observer/filing/0000950170-24-066242.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.